#Hong Kong #WuXi Biologics #Sustainability Report #CRDMO

Driving Impact Through Responsibility

WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), has made headlines with its 2024 Sustainability Report. This document vividly illustrates the company's unyielding commitment to sustainable development and clear progression in various crucial environmental and social dimensions.

A Unified Business Model Fostering Sustainability

WuXi Biologics harnesses a distinctive CRDMO business model combined with advanced technological capabilities to drive implementation on their strategies. The slogan “Follow and Win the Molecule” symbolizes the company’s focus on supporting clients at every stage of biologics development. The advancements discussed in the report showcase significant sustainability efforts made throughout 2024, underlining the impact of their operational strategies on both healthcare and the environment.

Dr. Chris Chen, the CEO of WuXi Biologics, articulated the company’s vision by emphasizing that sustainable operations are integral to achieving long-term success. He noted, “Our business growth is intrinsically linked with our accountability to society and the environment.” This philosophy drives the company to provide comprehensive Green CRDMO solutions aimed at facilitating clients’ sustainability journeys.

Enhancing Governance with Transparency

In pursuit of effective corporate governance, WuXi Biologics adheres to a well-defined sustainability strategy that aligns with the United Nations Sustainable Development Goals (UN SDGs). This approach not only establishes tangible and quantifiable ESG targets but also fosters a transparent dialogue with all stakeholders.

WuXi Biologics has become an active member of the Pharmaceutical Supply Chain Initiative (PSCI), truly embodying principles that enhance ethical operations, respect for human rights, and environmental responsibility. Their collaboration with global suppliers nurtures best practices that bolster positive societal impacts, enabling a robust corporate framework focused on sustainability.

Community Engagement and Employee Empowerment

The dedication shown by the workforce at WuXi Biologics plays a crucial role in their sustainability narrative. The company prides itself on its diverse and committed team, comprising 53 nationalities. Notably, WuXi Biologics places significant emphasis on empowering women in STEM fields, with female employees occupying 54% of their STEM roles, well above the industry average.

The company's community engagement efforts have been profound in 2024, logging almost 10,000 hours in volunteer work across various localities. This initiative reflects WuXi Biologics’ overarching goal to create social value and improve patient outcomes through groundbreaking treatments, particularly for rare diseases where they actively support numerous integrated projects.

Climate Change Mitigation and Environmental Stewardship

With climate change being a pressing global challenge, WuXi Biologics recognizes the urgency and necessity of promoting environmental stewardship. Their commitment extends beyond compliance, with fascinating statistics revealing a 30% reduction in greenhouse gas emissions and a 28% decrease in water consumption since 2020 and 2019, respectively.

The company demonstrates its dedication by incorporating eco-friendly practices and solutions in their innovative technology platforms, integrating sustainability into the biopharmaceutical development process. Their advanced Green CRDMO solutions drastically reduce the carbon footprint of projects, which even received acknowledgment from the United Nations Global Compact, highlighting the operational excellence reflected through sustainable practices.

Recognition and Future Vision

The sustainability efforts of WuXi Biologics have not gone unnoticed, earning the company multiple accolades, including an MSCI AAA Rating and inclusion in prominent sustainability indices. Their commitment to driving sustainable practices also aligns with the company's focus on operational excellence, where over 90% of their improvement projects yielded significant ESG benefits in 2024.

As WuXi Biologics aims for future milestones, Dr. Chen encourages continued commitment to sustainability as a focal point for innovation and operational strategy. With initiatives aimed at accelerating progress towards the UN SDGs, they strive to deliver transformative treatments to patients worldwide, ensuring that care is both effective and responsible.

In conclusion, the 2024 Sustainability Report from WuXi Biologics serves as a beacon of their dedication to fostering a sustainable future, advocating for ethical governance, community empowerment, and environmental action, ultimately aiming to create shared success for all stakeholders involved in the biopharmaceutical industry.